Key result
The arrhythmogenic dilated cardiomyopathy phenotype was associated with a higher incidence of sudden cardiac death, sustained ventricular tachycardia, or ventricular fibrillation compared with non-arrhythmogenic DCM (30.3% vs 17.6%, P=0.022).
Why the study?
Does an arrhythmogenic phenotype in dilated cardiomyopathy predict an increased risk of life-threatening arrhythmias?
Cohort (n=285)
Does an arrhythmogenic phenotype in dilated cardiomyopathy predict an increased risk of life-threatening arrhythmias?
Absolute Event Rate: 30.3% vs 17.6%
p-value: p=0.022
One-third of DCM patients exhibit an arrhythmogenic phenotype, which, along with a family history of ventricular arrhythmias, predicts an increased risk of sudden cardiac death and life-threatening arrhythmias.
No takes yet. Share an insight, caveat, or question.
Supports considering arrhythmogenic features in DCM risk stratification; leaves open need for prospective validation before guiding therapy.
Spezzacatene et al. (2015) conducted a cohort in Dilated cardiomyopathy (n=285). Arrhythmogenic DCM (AR-DCM) phenotype vs. Non-AR-DCM phenotype was evaluated on Sudden cardiac death (SCD), sustained ventricular tachycardia (SVT), or ventricular fibrillation (VF) (p=0.022). The arrhythmogenic dilated cardiomyopathy phenotype was associated with a higher incidence of sudden cardiac death, sustained ventricular tachycardia, or ventricular fibrillation compared with non-arrhythmogenic DCM (30.3% vs 17.6%, P=0.022).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: